Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

This study has been completed.
Sponsor:
Collaborator:
University of Texas
Information provided by (Responsible Party):
Oncolytics Biotech
ClinicalTrials.gov Identifier:
NCT00998322
First received: October 15, 2009
Last updated: April 8, 2015
Last verified: April 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2015
  Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)